Related Experiment Video

Updated: Sep 26, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

[Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis]

A L Guerrero1, V Bueno, M T Hernández

  • 1Unidad de Neurología, Hospital Río Carrión, Palencia, Spain. aguerrerop@medynet.com

Neurologia (Barcelona, Spain)
|April 5, 2003
PubMed
Abstract

Insights

The apolipoprotein E e4 allele does not predict multiple sclerosis progression. This study found no significant correlation between the e4 allele and disease markers in patients with multiple sclerosis.

Area of Science:

  • Neuroimmunology
  • Genetics
  • Neurology

Context:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • The apolipoprotein E (APOE) gene, particularly the e4 allele, has been investigated as a potential predictor of disease progression in MS.

Purpose:

  • To investigate the association between the apolipoprotein E e4 allele and markers of disability progression in patients with multiple sclerosis.

Summary:

  • This study analyzed 42 patients with relapsing-remitting or secondary progressive multiple sclerosis.
  • Correlations between the APOE e4 allele and various progression markers (age of onset, disease duration, relapses, EDSS, progression index, relapse rate) were assessed.
  • No statistically significant correlation was found between the presence of the APOE e4 allele and any of the evaluated progression parameters.

Impact:

  • The findings suggest that APOE e4 may not be a reliable predictor of multiple sclerosis progression in the studied cohort.
  • Further research with larger sample sizes is needed to definitively confirm or refute this association.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...